The FDA Group's CEO, Nick Capman sits down with Divya Gowdar, Founder and CEO of NubGenix to discuss the pitfalls and lessons learned on the frontlines of audit and inspection readiness throughout the FDA-regulated industries.
Discussion points include:
Divya's top 5 takeaways:
Divya is a performance-driven and hands-on Quality leader and professional with extensive experience in the medical device and combination product industry. She has contributed significantly to quality management systems, product development lifecycle, risk management, quality compliance, quality management review, inspection management, training, change controls, supplier management, complaint management, and technical operations.
Who is The FDA Group? The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. https://www.thefdagroup.com/
A Journey into Life Sciences Investment: Strategies, Challenges, and Opportunities with Sal Buscemi
Navigating Risk Management in Medical Devices with Brian Dense
The DEA, FDA & Controlled Substances: An Insider's Perspective with Former DEA Agent Dennis Wichern
A Deep Dive into Medical Device Regulatory Strategy with Regulatory Attorney Christine P. Bump
Lessons from a Medtech Entrepreneur: Ram Konduru on Fostering Teamwork and Personal Growth in Leadership
Unlocking Effective Leadership: A Conversation with MetaComet Systems President, David Marlin
Leadership, Management, and Enhancing Quality of Life: A Conversation with Dan Barker, CEO of Wikimotive
Navigating the 510(k) Process: A Q&A with Regulatory Consultant, Trey Thorsen, MS, RAC
The Future of Life Science Talent Acquisition: Securing In-Demand Skills in a Competitive Market
FDA Revives Its Proposed Quality Metrics Program for Pharma
Inspection Alternatives Are Driving More FDA Enforcement Actions: What It Means for Industry
FDA's Domestic Biopharma Inspections Return to Normal
Quality Management Review: Benchmarking Quantitatively!
Addressing FDA's Inspection Backlog with Mary Denigan-Macauley, GAO's Director of Health Care
FDA's Fraudulent Products Task Force and Operation Quack Hack Battle COVID Vaccine Scams
What to Expect for the FDA's Regulation of Medical Devices & Digital Health Under the Biden Administration
Clinical Outsourcing & Insourcing: Selecting the Right Model or Mix
What RA/QA/Clinical Leaders Should Expect From the FDA in 2021
Inside FDA Pre-Approval Inspections with Former FDA Investigator, Christopher Smith
A Look at FDA's Pandemic Inspections Q&A Guidance
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Ground Truths